Is Johnson & Johnson (JNJ) Stock a Buy After Its Prostate Cancer Pill Results?
Image: CoinCentral
TLDR JNJ stock fell 1.42% to $263.81 on Friday. J&J’s Phase 1 data for JNJ-6143 showed a 75% tumor response among patients with measurable disease at the 50 mg dose. 77% of patients had a PSA drop of at least 50%, and 48% saw a drop of at least 90%. The most common side effects were high cholesterol, nausea and high triglycerides, and one patient stopped treatment. Analysts rate JNJ a Moderate Buy with an average price target of $288.71, about 9% above the current price. Johnson & Johnson (JNJ) stock closed Friday at $263.81, down 1.42%. The move came before the company released new cancer data on Sunday. Johnson & Johnson, JNJ J&J reported Phase 1 results for JNJ-6143, an experimental once-daily prostate cancer pill.
Read the full story on CoinCentralBeCrypto News shows a short excerpt and links to the publisher. The full report belongs to CoinCentral.
